$ARIA Recent News Six stocks to watch 3:27 p.m. Feb.

New Post Public Reply Private Reply Replies (0) Message Board

Dec 9, 2014 at 10:02 AM

$ARIA Recent News

Six stocks to watch 3:27 p.m. Feb. 26, 2014 - The Trading Deck
6 stocks to watch 3:34 p.m. Feb. 12, 2014 - The Trading Deck
Ariad falls after wild ride upward, while Care.com holds on to its gains 9:02 p.m. Jan. 27, 2014 - Russ Britt
Apple green ahead of earnings; Caterpillar tops gainers 3:42 p.m. Jan. 27, 2014 - Sue Chang
Ariad shares jump nearly 30% on rumors of Big Pharma takeover 1:43 p.m. Jan. 24, 2014 - Russ Britt
5 charts to watch 3:52 p.m. Jan. 15, 2014 - The Trading Deck
Apple closes lower; B. of A. rises on analyst call 4:15 p.m. Jan. 2, 2014 - Wallace Witkowski
Apple gains on China Mobile deal; homebuilders rally 3:33 p.m. Dec. 23, 2013 - Wallace Witkowski
Suspension is lifted for Ariad's leukemia drug 6:33 a.m. Dec. 23, 2013 - MarketWatch.com
J.C. Penney and more of the year's most profitable shorts 3:23 p.m. Dec. 9, 2013 - blogs.marketwatch.com
Hewlett-Packard, a cyclical green light and why silver is in trouble 8:50 a.m. Nov. 26, 2013 - Shawn Langlois
Ariad takes another pounding after leukemia treatment is pulled 12:14 p.m. Oct. 31, 2013 - Russ Britt
H-P has best day in four months on upbeat outlook 3:34 p.m. Oct. 9, 2013 - Sue Chang
Ariad plummets 70% after drug test patients have serious clotting issues 10:38 a.m. Oct. 9, 2013 - Russ Britt
FDA places partial hold on Ariad's Iclusig trials 7:16 a.m. Oct. 9, 2013 - MarketWatch.com
Dan Loeb makes bet on Disney 7:06 p.m. Aug. 14, 2013 - David Benoit
Onyx share surge lifts several boats in biotech harbor, including ETFs 10:33 a.m. July 1, 2013 - Russ Britt
SAC Capital Advisors likes this pharma stock 3:24 p.m. April 18, 2013 - Insider Monkey
Ariad Pharma up 6% to $20.09 10:35 a.m. Dec. 17, 2012 - Steve Gelsi
FDA OKs Iclusig to treat rare types of leukemia 1:06 p.m. Dec. 14, 2012 - MarketWatch.com

ARIAD Reports Follow-up Data from Phase 1, PACE Trials of Ponatinib for T315I Mutation 6:37 a.m. Today - benzinga.com
ARIAD Reports Long-term Safety, Efficacy Data of Ponatinib from Phase 2 Pace Trial: 83% of CP-CML Patients Achieved Response 6:36 a.m. Dec. 8, 2014 - benzinga.com
Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's Post-Market Leader Stock 7:06 p.m. Dec. 3, 2014 - TheStreet.com
ARIAD Pharmaceuticals (ARIA) Is Strong On High Volume Today 10:00 a.m. Dec. 2, 2014 - TheStreet.com
Hottest Healthcare Stocks Now – AVNR BIIB ARIA ACHN 6:15 a.m. Dec. 2, 2014 - InvestorPlace.com
Vargatef cleared in Europe for lung cancer 9:23 a.m. Nov. 28, 2014 - Seeking Alpha
Ariad Pharmaceuticals (ARIA) Jumps: Stock Gains 9.7% - Tale of the Tape 9:25 a.m. Nov. 25, 2014 - Zacks.com
Iclusig cleared in Australia 10:41 a.m. Nov. 24, 2014 - Seeking Alpha
ARIAD Pharmaceuticals (ARIA) Strong On High Relative Volume Today 10:04 a.m. Nov. 24, 2014 - TheStreet.com
Biggest Movers in Healthcare Stocks Now – ARIA PTCT PTCT CLDX 6:30 a.m. Nov. 24, 2014 - InvestorPlace.com
Biggest Movers in Healthcare Stocks Now – ACAD CYH STJ PODD 6:30 a.m. Nov. 21, 2014 - InvestorPlace.com
Biggest Movers in Healthcare Stocks Now – CLDX ARIA KND MDCO 6:45 a.m. Nov. 20, 2014 - InvestorPlace.com
'Mad Money' Lightning Round: A Group to Avoid 6:00 a.m. Nov. 14, 2014 - TheStreet.com
Cramer's Lightning Round - Affymetrix Teased And Disappointed, But Is A Buy (11/13/14) 3:40 a.m. Nov. 14, 2014 - Seeking Alpha
10-Q: ARIAD PHARMACEUTICALS INC 4:53 p.m. Nov. 7, 2014 - Edgar Online - (EDG = 10Q, 10K)
Credit Suisse Expects New Pricing To Boost Sales For Ariad Pharmaceuticals 8:58 a.m. Nov. 6, 2014 - benzinga.com
Ariad Pharmaceuticals' (ARIA) CEO Harvey Berger on Q3 2014 Results - Earnings Call Transcript 12:47 p.m. Nov. 5, 2014 - Seeking Alpha
Ariad updates guidance after Q3 results 9:49 a.m. Nov. 5, 2014 - Seeking Alpha
ARIAD Pharmaceuticals (ARIA) Q3 2014 Results - Earnings Call Webcast 8:25 a.m. Nov. 5, 2014 - Seeking Alpha
Notable earnings before Wednesday’s open 5:30 p.m. Nov. 4, 2014 - Seeking Alpha

ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial 7:35 a.m. Dec. 8, 2014 - BusinessWire - BZX
Insider Trading Alerts for Hertz, Ariad Pharmaceuticals, J C Penney, Sirius XM, Apple, and Sunedison 8:45 a.m. Nov. 25, 2014 - PR Newswire - PRF
ARIAD and STA Announce Approval of Iclusig (Ponatinib) in Australia 7:35 a.m. Nov. 24, 2014 - BusinessWire - BZX
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene 9:10 a.m. Nov. 14, 2014 - PR Newswire - PRF
ARIAD Announces Iclusig Data Presentations at Annual American Society of Hematology Meeting 9:44 a.m. Nov. 6, 2014 - BusinessWire - BZX
ARIAD Reports Third Quarter 2014 Financial Results and Development Progress 7:36 a.m. Nov. 5, 2014 - BusinessWire - BZX
ARIAD to Present at the Stifel 2014 Healthcare Conference 7:35 a.m. Nov. 4, 2014 - BusinessWire - BZX
ARIAD Announces Adoption of Final Opinion for Iclusig by Committee for Medicinal Products for Human Use in Europe 6:35 a.m. Oct. 24, 2014 - BusinessWire - BZX
Insider Trading Alerts for Micron, CSX, Ariad Pharmaceuticals, IBM, SinoCoking Coal and Coke Chemical, and MannKind 7:55 a.m. Oct. 21, 2014 - PR Newswire - PRF
Insider Trading Research for Halliburton, Ariad Pharmaceuticals, KeyCorp, GoPro, MannKind, and Plug Power 7:45 a.m. Oct. 20, 2014 - PR Newswire - PRF
Biotech Equities Technical Analysis - ARIAD Pharma, Novavax, Galena Biopharma, Geron, and Celldex Therapeutics 7:40 a.m. Oct. 15, 2014 - PR Newswire - PRF
ARIAD to Webcast Conference Call on Third Quarter 2014 Financial Results 6:35 a.m. Oct. 15, 2014 - BusinessWire - BZX
ARIAD Announces Recommendation for Iclusig by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency 6:44 a.m. Oct. 10, 2014 - BusinessWire - BZX
ARIAD and Bellicum Announce Revised License Agreement for ARIAD’s Cell-Signaling Technology 6:35 a.m. Oct. 6, 2014 - BusinessWire - BZX
ARIAD’s AP26113 Receives FDA Breakthrough Therapy Designation For ALK+ Non-Small Cell Lung Cancer Resistant to Crizotinib 6:35 a.m. Oct. 2, 2014 - BusinessWire - BZX
ARIAD Presents Updated Clinical Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer 6:35 a.m. Sept. 29, 2014 - BusinessWire - BZX
INNATE PHARMA APPOINTS PIERRE DODION AS CHIEF MEDICAL OFFICER AND MEMBER OF THE EXECUTIVE COMMITTEE 11:41 a.m. Sept. 16, 2014 - GlobeNewswire
Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen 7:55 a.m. Sept. 4, 2014 - PR Newswire - PRF
Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 12:19 p.m. Aug. 19, 2014 - PR Newswire - PRF
ARIAD Reports Second Quarter 2014 Financial Results and Development Progress 10:34 p.m. Aug. 6, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Medical Device Manufacturing: $135B Market by 2031

Skyrocketing Demand in Medical Device Manufacturing You're looking at a market that's gearing up to hit a whopping $135.47 billion by 2031. That's a big leap from its $85.59 billion stature in 2026, showing a strong 9.6% compound annual growth rate (CAGR). Now, if that doesn't get your investor rollercoaster senses tingling, I don't know what will. Key Growth Drivers The...

LabWare Loop: A Game Changer for Lab Data Integrity

Breaking Down Silos in Lab Environments When it comes to the controlled chaos of laboratory operations, data integrity is the name of the game. We're talking about a new way of doing things that doesn't demand a physics degree just to connect the dots between gizmos and databases. Enter LabWare Loop, a solution that's rewriting the data playbook by linking multi-vendor...

DERMALOG Bolsters Biometric Defense with Key Wins

DERMALOG Rides High with PAD Success Germany-based DERMALOG just gave biometric crooks a run for their money. In a testament to gutsy tech work, they've hit a homerun with the latest independent security evaluations. They’ve managed to spot and shut down all 1,500 tried and tested spoofs in presentation attacks—think photos, videos, and phony fingerprints. That’s no...

Vertiv's Explosive Q3 Growth: A 2026 Power Move

Vertiv's Third Quarter Triumph Imagine a company blowing past expectations like a hot knife through butter—yeah, that's Vertiv for you in 2026. These guys didn’t just ride the wave; they created a tsunami in the digital infrastructure sector. Net sales ballooned by a staggering 61% compared to last year's same quarter, pulling in $4.313 billion. When you consider the...

Seatrium & Karpowership Boost Southeast Asia's Energy Future

Anchoring Ambitions: A Fresh Power Pact Seatrium Limited and Karpowership are rolling up their sleeves for a tough yet lucrative mission in Southeast Asia. These two powerhouses are pooling their expertise to beef up the region’s energy supply through floating power solutions and digital infrastructure. You gotta give it to them—they’re not skimping on the ambition....

North Fork Mono Casino Opens: A $750 Million Bet

A New Spin in Madera Cue the fanfare, folks! The North Fork Mono Casino just threw open its doors earlier than expected today, marking a hefty $750 million wager right in the heart of California's Central Valley. It's a big deal managed by Station Casinos, part of Red Rock Resorts, Inc. (NASDAQ: RRR)—teaming up with the North Fork Rancheria of Mono Indians for a...

US State Dept. & IICA: Strengthening Disaster Response

Bridging Borders to Tackle Disasters It seems like everyone and their grandma talks disaster aid, but when two giants like the US State Department's Bureau of Disaster and Humanitarian Response (DHR) and the Inter-American Institute for Cooperation on Agriculture (IICA) grab a coffee—real serious action is brewing. Why This Matters The partnership's not just talk. Let's...

Total Play's Q3 2026: Subscriber Surge, Debt Down

Subscriber Growth Amidst Financial Hurdles Here’s the deal with Total Play's third-quarter results for 2026: they’ve got a mixed bag of numbers that’ll make any investor think twice. The headline is a hefty rise in subscribers—a net gain of 143,340 in the Residential segment thanks to their top-tier internet services. But don’t start cheering just...

Archera Raises $15M to Redefine Cloud Commitment Models

Rethinking Cloud and AI Contracts A new day in cloud economics has dawned, folks, and it’s shining over Archera, a name you'll want to remember if you're navigating the murky waters of cloud and AI spending. As the world dashes headlong into AI, cloud investments are becoming a game of either overcommitting or missing out on key discounts. Archera's snagged a $15...

Covalent's Bet on AML Analytics: A Defense Revolution

The Big Play: AI Meets Financial Defense You know when a private equity firm swoops in, it's like the cavalry arriving. Covalent Equity Partners just did that for AML Analytics, or AMLA for short. A payday for them, sure, but it's more about amplifying AMLA's already hefty punch against financial crime, using AI to boot. Now, if AI's mentioned, you know someone's getting...